Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate the effect of long-term administration of Rimonabant on the time of progression
to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or
Impaired Glucose Tolerance (IGT) or both at baseline).
Secondary objectives:
- To assess the effect on weight loss and weight maintenance; sustained effect following a
washout period, effect on other markers of glycemic control (fasting glucose,
fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose
tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG),
- To assess the effect on quality of life
- To evaluate long term safety and tolerability.